News beyond our pages

Wang et al (Nat Med 2025 Jan 7; https://doi.org/10.1038/s41591-024-03419-3) conducted a placebo-controlled, randomized, phase 3 trial to evaluate the safety and efficacy of suraxavir marboxil, an oral inhibitor of influenza polymerase acidic protein (PA), in acute uncomplicated influenza. Nearly 600 outpatients aged 5 to 65 years were given a single dose of suraxavir or placebo within 2 days of symptom onset. Suraxavir decreased the median time to alleviation of symptoms by over 20 hours and reduced viral load within 24 hours as compared to placebo.